| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.96B | 1.70B | 1.08B | 820.22M | 625.49M | 391.00M |
| Gross Profit | 1.24B | 1.02B | 492.74M | 363.97M | 307.07M | 187.38M |
| EBITDA | -211.86M | -148.08M | -383.28M | -507.03M | -451.54M | -205.95M |
| Net Income | -253.24M | -190.43M | -434.80M | -547.80M | -471.72M | -229.74M |
Balance Sheet | ||||||
| Total Assets | 1.76B | 1.66B | 1.44B | 1.39B | 1.24B | 932.15M |
| Cash, Cash Equivalents and Short-Term Investments | 1.02B | 968.28M | 878.98M | 898.39M | 914.28M | 737.27M |
| Total Debt | 196.13M | 187.12M | 441.99M | 446.22M | 397.23M | 281.09M |
| Total Liabilities | 510.88M | 465.31M | 676.37M | 688.73M | 583.18M | 445.92M |
| Stockholders Equity | 1.25B | 1.20B | 765.33M | 705.74M | 653.30M | 486.24M |
Cash Flow | ||||||
| Free Cash Flow | 104.56M | 69.24M | -286.15M | -479.20M | -376.27M | -202.12M |
| Operating Cash Flow | 186.70M | 135.66M | -246.96M | -431.50M | -335.24M | -182.51M |
| Investing Cash Flow | -9.29M | 137.62M | 168.50M | 330.34M | -205.19M | -331.46M |
| Financing Cash Flow | 25.81M | 30.20M | 254.46M | 482.64M | 576.19M | 500.85M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $26.42B | -101.10 | -24.32% | ― | 44.38% | 22.87% | |
| ― | $15.39B | 12.71 | 68.11% | ― | -3.32% | ― | |
| ― | $12.24B | -11.71 | -35.51% | ― | 12.56% | -464.28% | |
| ― | $726.66M | -13.97 | -4.54% | ― | 4.31% | 69.57% | |
| ― | $1.38B | -12.45 | -11.76% | ― | 9.70% | -30.94% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $9.00B | -21.18 | ― | ― | 28.74% | 18.25% |
Natera Inc. Reports Strong Quarter with Record Revenue Growth and Strategic Advancements
Natera, Inc. is a global leader in cell-free DNA and genetic testing, focusing on oncology, women’s health, and organ health, with operations in ISO 13485-certified and CAP-accredited laboratories in Austin, Texas, and San Carlos, California.